newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

  • IGC Pharma announced a 65% enrollment milestone for its Phase 2 CALMA trial evaluating IGC-AD1 for Alzheimer's agitation.
  • The company aims to complete the trial in early 2026, supported by an accelerated enrollment rate.
  • Recruitment utilized a hybrid strategy where 25% of participants joined via targeted social-media campaigns & 75% through direct clinical-site efforts.
  • CEO Ram Mukunda stated the strategy expanded patient access while maintaining high data quality.
  • Agitation affects over 76% of individuals with Alzheimer's disease, & interim trial analyses showed statistically significant reductions in symptoms.
  • IGC Pharma is expanding clinical operations across the United States & Canada.
  • The company's pipeline includes IGC-AD1 (cannabinoid-based), TGR-63 (amyloid plaques), & early-stage programs targeting neurodegeneration & metabolic dysfunctions.
  • Forward-looking statements include risks regarding regulatory approval, AI performance, economic conditions, & FDA positions on cannabis products.